Working… Menu
Trial record 2 of 6 for:    ibrutinib aml

Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02635074
Recruitment Status : Terminated (safety)
First Posted : December 18, 2015
Last Update Posted : May 14, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Steven E. Coutre, Stanford University

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : July 18, 2017
Actual Study Completion Date : November 10, 2017